Nitric oxide and prostaglandins potentiate the liver regeneration cascade

Canadian Journal of Gastroenterology

Volumn 20, Issue 5, 2006, Pages 329-334

  Schoen Smith, Jodi M ^a   Lautt, W Wayne ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Liver regeneration; Nitric oxide; Prostaglandins; Two thirds partial hepatectomy

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; MESSENGER RNA; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE; NITRIC OXIDE DONOR; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTAGLANDIN; PROTEIN C FOS; RNA; ZAPRINAST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; LIVER REGENERATION; LIVER RESECTION; LIVER WEIGHT; MALE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RNA ISOLATION; SURGICAL TECHNIQUE;

EID: 33745247427     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2006/659027     Document Type: Article

References (34)

1. Wang HH, Lautt WW. Does nitric oxide (NO) trigger liver regeneration? Proc West Pharmacol Soc 1997;40:17-8.
2. Wang HH, Lautt WW. Hepatocyte primary culture bioassay - A simplified tool to assess the initiation of the liver regeneration cascade. J Pharmacol Toxicol Meth 1997;38:141-50.
3. Wang HH, Lautt WW. Evidence of nitric oxide, a flow-dependent factor, being a trigger of liver regeneration in rats. Can J Physiol Pharmacol 1998;76:1072-9.
4. Schoen JM, Wang HH, Minuk GY, Lautt WW. Shear stress-induced nitric oxide release triggers the liver regeneration cascade. Nitric Oxide 2001;5:453-64.
5. 2 and rat liver regeneration. Gastroenterology 1993; 105:495-9.
6. Lai OF, Chow PK, Tan S, et al. Changes in prostaglandin and nitric oxide levels in the hyperdynamic circulation following liver resection. J Gastroenterol Hepatol 2000;15:895-901.
7. Rudnick DA, Perlmutter DH, Muglia LJ. Prostaglandins are required for CREB activation and cellular proliferation during liver regeneration. Proc Natl Acad Sci USA 2001;98:8885-90.
8. MacManus JP, Braceland BM. A connection between the production of Prostaglandins during liver regeneration and the DNA synthetic response. Prostaglandins 1976;11:609-20.
9. 2 production is amplified during hepatic regeneration. Hepatology 1991;14:368-72.
10. Obolenskaya MY, Vanin AF, Mordvintcev PI, Mulsch A, Decker K. EPR evidence of nitric oxide production by the regenerating rat liver. Biochem Biophys Res Commun 1994;202:571-6.
11. Rai RM, Lee FY, Rosen A, et al. Impaired liver regeneration in inducible nitric oxide synthase-deficient mice. Proc Natl Acad Sci USA 1998;95:13829-34.
12. Camovale CE, Scapini C, Alvarez ML, Favre C, Monti J, Carrillo MC. Nitric oxide release and enhancement of lipid peroxidation in regeneration rat liver. J Hepatol 2000;32:798-804.
13. Zeini M, Hortelano S, Traves PG, Martin-Sanz P, Bosca L. Simultaneous abrogation of NOS-2 and COX-2 activities is lethal in partially hepatectomised mice. J Hepatol 2004;40:926-33.
14. Moser MJ, Gong Y, Zhang MN, et al. Immediate-early oncogene expression and liver function following varying extents of partial hepatectomy in the rat. Dig Dis Sci 2001;46:907-14.
15. Haby C, Lisovoski F, Aunis D, Zwiller J. Stimulation of the cyclic GMP pathway by NO induces expression of the immediate early genes c-fos and junB in PC12 cells. J Neurochem 1994;62:496-501.
16. Morris BJ. Stimulation of immediate early gene expression in striatal neurons by nitric oxide. J Biol Chem 1995;270:24740-4.
17. 1 subtype of PGE receptor in mouse osteoblastic MC3T3-E1 cells. Calcif Tissue Int 2000;66:217-23.
18. 2-mediated c-fos mRNA induction by interleukin-4 in murine macrophages. J Biochem 2000;127:451-6.
19. Glantschnig H, Varga, F, Klaushofer K. The cellular protooncogenes c-fos and egr-1 are regulated by prostacyclin in rodent osteoblasts and fibroblasts. Endocrinology 1996;137:4536-41.
20. 2): A potential mediator of c-fos expression induced by hydrostatic pressure in osteoblastic cells. Eur J Clin Invest 1996; 26:544-8.
21. Katsuki S, Murad F. Effects of sodium nitro prusside, nitroglycerin and sodium azide on cyclic GMP levels in various tissues. Clin Res 1977;25:32A. (Abst)
22. Thompson WJ. Cyclic nucleotide phosphodiesterases: Pharmacology, biochemistry and function. Pharmac Ther 1991;51:13-33.
23. Higgins GM, Anderson RM. Experimental pathology of the liver: I. Restoration of the liver of the white rat following partial surgical removal. Arch Pathol 1931;12:186-202.
24. Curran T, MacConnell WP, van Straaten F, Verma IM. Structure of the FBJ murine osteosarcoma virus genome: Molecular cloning of its associated helper virus and the cellular monolog of the V-fos gene from mouse and human cells. Mol Cell Biol 1983;3:914-21.
25. Levy JV. Prostacyclin-induced contraction of isolated aortic strips from normal and sportaneously hypertensive rats (SHR). Prostaglandins 1980;19:517-25.
26. Freelisch M. The use of nitric oxide donors in pharmacological studies. N S Arch Pharmacol 1998;358:113-22.
27. Ng SS, Pang CC. Zaprinast, a type V phosphodiesterase inhibitor, dilates capacitance vessels in anaesthetised rats. Eur J Pharmacol 1998;351:323-8.
28. Gibson A. Phosphodiesterase 5 inhibitors and nitrergic transmission - from zaprinast to sildenafil. Eur J Pharmacol 2001;411:1-10.
29. Abe Y, Tatsumi K, Sugito K, Ikeda Y, Kimura H, Kuriyama T. Effects of inhaled prostacyclin analogue on chronic hypoxic pulmonary hypertension. J Cardiovasc Pharmacol 2001;37:239-51.
30. Fink AN, Frishman WH, Azizad M, Agarwal Y. Use of prostacyclin and its analogues in the treatment of cardiovascular disease. Heart Dis 1999;1:29-40.
31. Hill LL, Pearl RG. Combined inhaled nitric oxide and inhaled prostacyclin during experimental chronic pulmonary hypertension. J Appl Physiol 1999;86:1160-4.
32. Ziesche R, Petkov V, Wittmann K, et al. Treatment with epoprostenol reverts nitric oxide non-responsiveness in patients with primary pulmonary hypertension. Heart 2000;83:406-9.
33. Neumann UP, Kaisers U, Langrehr JM, et al. Administration of prostacyclin after liver transplantation: A placebo controlled randomized trial. Clin Transplant 2000;14:70-4.
34. 2 analog on liver grafts subjected to 30 minutes of warm ischemia. Surg Today 1997;27:1056-60.